In 2001, Serfaty et al. first reported that sequential therapy with lamivudine and IFN-α can induce a sustained virologic response, including HBs seroconversion, in patients with chronic hepatitis B not responding to IFN-alpha alone [6]. This evidence concerns the gene IFNA2 and chronic hepatitis B virus infection.